Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$3.10 -3.1%	$3.11	$2.01 ▼ $5.64	$212.88M	1.61	1.20 million shs	1.55 million shs
DSGN Design Therapeutics	$3.95 -0.5%	$3.87	$2.60 ▼ $7.77	$225.37M	1.62	180,537 shs	74,466 shs
GOSS Gossamer Bio	$1.36 -1.4%	$1.14	$0.66 ▼ $1.55	$313.68M	1.85	1.38 million shs	1.30 million shs
IMRX Immuneering	$3.02 +2.7%	$1.71	$1.00 ▼ $3.83	$105.80M	0.01	2.53 million shs	2.28 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	+1.27%	-13.51%	+5.61%	-9.60%	+35.59%
DSGN Design Therapeutics	+1.79%	+7.88%	+4.20%	-4.34%	+18.15%
GOSS Gossamer Bio	+0.73%	+11.29%	+15.00%	+16.95%	+67.05%
IMRX Immuneering	+20.49%	+61.54%	+90.91%	+79.27%	+97.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDF Cardiff Oncology	1.4861 of 5 stars	3.4	0.0	0.0	3.0	0.0	0.6
DSGN Design Therapeutics	0.3878 of 5 stars	1.0	1.0	0.0	0.6	2.5	0.6
GOSS Gossamer Bio	3.2832 of 5 stars	3.5	1.0	4.7	0.0	1.7	0.0
IMRX Immuneering	3.5617 of 5 stars	3.3	2.0	0.0	3.9	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	2.80	Moderate Buy	$9.88	218.55% Upside
DSGN Design Therapeutics	2.00	Hold	$4.00	1.27% Upside
GOSS Gossamer Bio	3.00	Buy	$7.33	439.22% Upside
IMRX Immuneering	2.60	Moderate Buy	$13.25	338.74% Upside

Current Analyst Ratings Breakdown

Latest IMRX, CRDF, GOSS, and DSGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/18/2025	IMRX Immuneering	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $10.00
6/18/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/18/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/5/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/9/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
5/7/2025	IMRX Immuneering	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $21.00
5/6/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$680K	303.30	N/A	N/A	$1.86 per share	1.67
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$4.28 per share	N/A
GOSS Gossamer Bio	$114.70M	2.70	N/A	N/A	$0.13 per share	10.46
IMRX Immuneering	$320K	339.66	N/A	N/A	$1.33 per share	2.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
DSGN Design Therapeutics	-$49.59M	-$0.99	N/A	N/A	N/A	N/A	-22.85%	-22.02%	8/4/2025 (Estimated)
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-41.12%	-128.98%	-15.52%	8/11/2025 (Estimated)
IMRX Immuneering	-$61.04M	-$1.96	N/A	N/A	N/A	N/A	-119.22%	-99.22%	8/5/2025 (Estimated)

Latest IMRX, CRDF, GOSS, and DSGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/14/2025	Q1 2025	DSGN Design Therapeutics	-$0.28	-$0.31	-$0.03	-$0.31	N/A	N/A
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million
5/5/2025	Q1 2025	IMRX Immuneering	-$0.41	-$0.42	-$0.01	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	6.22	6.22
DSGN Design Therapeutics	N/A	28.37	28.37
GOSS Gossamer Bio	6.70	5.71	5.71
IMRX Immuneering	N/A	7.48	7.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
DSGN Design Therapeutics	56.64%
GOSS Gossamer Bio	81.23%
IMRX Immuneering	67.65%

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	7.70%
DSGN Design Therapeutics	31.20%
GOSS Gossamer Bio	6.70%
IMRX Immuneering	22.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
DSGN Design Therapeutics	40	56.77 million	39.06 million	Optionable
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable
IMRX Immuneering	60	35.99 million	27.75 million	Not Optionable

IMRX, CRDF, GOSS, and DSGN Headlines

Recent News About These Companies

Immuneering Corporation (NASDAQ:IMRX) Insider Brett Matthew Hall Acquires 6,007 Shares

June 25 at 5:56 AM | insidertrades.com

Immuneering Corporation (NASDAQ:IMRX) Insider Brett Matthew Hall Purchases 6,007 Shares

June 24 at 11:21 AM | marketbeat.com

Insider Buying: Immuneering Corporation (NASDAQ:IMRX) Insider Buys 7,415 Shares of Stock

June 24 at 11:21 AM | marketbeat.com

Immuneering Corporation (NASDAQ:IMRX) Director Peter Feinberg Buys 25,000 Shares

June 23 at 11:36 AM | marketbeat.com

Immuneering Corporation (NASDAQ:IMRX) CEO Benjamin J. Zeskind Acquires 21,000 Shares

June 21, 2025 | insidertrades.com

Immuneering Corporation (NASDAQ:IMRX) Receives Average Recommendation of "Moderate Buy" from Brokerages

June 21, 2025 | marketbeat.com

We're A Little Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

June 20, 2025 | finance.yahoo.com

Insider Buying: Immuneering Corporation (NASDAQ:IMRX) CEO Purchases 21,000 Shares of Stock

June 20, 2025 | marketbeat.com

Immuneering (NASDAQ:IMRX) Given "Buy" Rating at Needham & Company LLC

June 20, 2025 | americanbankingnews.com

Immuneering (NASDAQ:IMRX) Price Target Raised to $10.00 at Mizuho

June 20, 2025 | americanbankingnews.com

Pre-Market Most Active for Jun 17, 2025 : IMRX, TSLL, VERV, RUN, SQQQ, TQQQ, KO, CRCL, DIS, QBTS, BBAI, NIO

June 19, 2025 | nasdaq.com

Insider Buying: Immuneering Corporation (NASDAQ:IMRX) Director Acquires 40,485 Shares of Stock

June 19, 2025 | insidertrades.com

Chardan Capital Reaffirms Buy Rating for Immuneering (NASDAQ:IMRX)

June 19, 2025 | americanbankingnews.com

Positive Phase IIa OS data on Immuneering’s novel MEK inhibitor

June 18, 2025 | thepharmaletter.comT

Immuneering Corporation (NASDAQ:IMRX) Director Acquires $89,471.85 in Stock

June 18, 2025 | marketbeat.com

Immuneering (NASDAQ:IMRX) Price Target Raised to $10.00

June 18, 2025 | marketbeat.com

Chardan Capital Reiterates Buy Rating for Immuneering (NASDAQ:IMRX)

June 18, 2025 | marketbeat.com

Immuneering (NASDAQ:IMRX) Earns "Buy" Rating from Needham & Company LLC

June 18, 2025 | marketbeat.com

Immuneering Corporation to Host Conference Call for Phase 2a Clinical Trial Update on IMM-1-104 in Pancreatic Cancer

June 18, 2025 | nasdaq.com

Immuneering stock rises after positive pancreatic cancer trial data

June 17, 2025 | investing.com

Immuneering Shares Climb on Promising Pancreatic Cancer Trial Results

June 17, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX, CRDF, GOSS, and DSGN Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$3.10 -0.10 (-3.13%)

Closing price 04:00 PM Eastern

Extended Trading

$3.13 +0.03 (+1.10%)

As of 07:43 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Design Therapeutics NASDAQ:DSGN

$3.95 -0.02 (-0.50%)

Closing price 04:00 PM Eastern

Extended Trading

$4.04 +0.09 (+2.41%)

As of 07:45 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Gossamer Bio NASDAQ:GOSS

$1.36 -0.02 (-1.45%)

Closing price 04:00 PM Eastern

Extended Trading

$1.37 +0.01 (+0.74%)

As of 07:53 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Immuneering NASDAQ:IMRX

$3.02 +0.08 (+2.72%)

Closing price 04:00 PM Eastern

Extended Trading

$3.08 +0.06 (+2.15%)

As of 07:59 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time